OnKure Therapeutics, Inc. (OKUR) Stock Price & Analysis
OnKure Therapeutics, Inc. (OKUR) closed at USD 2.13 on Thursday, October 15, 2026, down 5.33% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.25; the Oct 15, 2026 session ranged USD 2.09–2.28 on volume of 349,905 shares. Market capitalization is $86.26M, with a 52-week range of USD 2.09–5.38 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OKUR.md
Key facts (OKUR)
- Analysts: Buy (mean 2.17 on a 1–5 scale) (6 analysts), mean target USD 15.5 (range 11–21).
- Total return with dividends: 1Y -26.0% vs S&P 500 +18.1%; 5Y -96.7% vs S&P 500 +85.1%.
Analysts (OKUR)
Consensus Buy (mean 2.17 on a 1–5 scale), 6 analysts; mean target USD 15.5 (low 11, high 21).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Oppenheimer | Target lowered | Outperform | $30 → $14 |
| 2026-07-20 | HC Wainwright & Co. | Target lowered | Buy | $27 → $21 |
Total return (dividends reinvested) (OKUR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -26.0% | -96.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.1% | -49.4% |
| Volatility (annualized) | 69.8% | 104.8% |
| Max drawdown | -59.6% (Apr 2026→Oct 2026) | -98.2% (Apr 2023→May 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 2.13 |
|---|---|
| Change | ▼ 5.33% (down) |
| Previous Close | USD 2.25 |
| Open | USD 2.26 |
| Day Range | USD 2.09 – 2.28 |
| 52-Week Range | USD 2.09 – 5.38 |
| Volume | 349,905 shares |
| Market Cap | $86.26M |
| Exchange | NGM |
Technical Analysis (OKUR)
Nexqual's technical model rates OKUR "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.14 (oversold) |
| vs SMA50 | Below (USD 3.26) |
| MACD | -0.29 (negative) |
Analyst Ratings (OKUR)
Wall Street analysts rate OKUR "Buy" based on 6 analysts, with a mean price target of USD 15.5 (range USD 11–21), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15.5 |
| High Target | USD 21 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (OKUR)
| EPS Estimate | USD -0.41 |
|---|---|
| Revenue Estimate | $125,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.31 vs est -0.54 ▲ beat |
| 2026-03-31 | USD -1.11 vs est -0.74 ▼ miss |
| 2025-12-31 | USD -0.99 vs est -1.15 ▲ beat |
| 2025-09-30 | USD -1.09 vs est -1.2 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (OKUR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -46.91% |
| Debt / Equity | 0.01 |
| Current Ratio | 26.75 |
| Total Cash | $176.39M |
| Total Debt | $926,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (OKUR)
Nexqual rates OnKure Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $176M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$48M (TTM) |
| Efficiency | Critical — ROE -47%, ROA -29.3% |
Ownership (OKUR)
| Insider Ownership | +10.17% |
|---|---|
| Institutional Ownership | +93.42% |
| Shares Outstanding | 40.50M |
| Float | 18.68M |
| Short % of Float | +3.36% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (OKUR)
OnKure Therapeutics, Inc. is led by Nicholas A. Saccomano (age 66), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Director | Nicholas A. Saccomano (age 66) |
|---|---|
| Chief Financial Officer | Jason A. Leverone (age 51) |
| Senior VP of Business Development & Director | Isaac Manke (age 48) |
| Chief Scientific Officer | Dylan Hartley (age 56) |
| Senior Vice President of Computational Drug Discovery | James Blake |
Major Backers & Investors (OKUR)
Notable institutional backers of OnKure Therapeutics, Inc. include RA Capital Management, L.P., BVF Inc., Acorn Capital Advisors, LLC , according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.9% |
| BVF Inc. | 8.01% |
| Acorn Capital Advisors, LLC | 7.03% |
| StepStone Group LP | 6.59% |
| Adar1 Capital Management, LLC | 5.54% |
| Vivo Capital, LLC | 4.77% |
| Vestal Point Capital, LP | 4.52% |
| Trails Edge Capital Partners, LP | 3.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.06% |
| BlackRock | 5.88% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt